NextCure, Inc. - 8-K Filing
NextCure reported first-quarter 2026 financial results with $29.7 million in cash, cash equivalents, and marketable securities as of March 31, 2026, down from $41.8 million in December 2025 due to $13.4 million in operational cash use. The company incurred a net loss of $9.8 million for the quarter, compared to $11.0 million in the same period in 2025. It also provided a business update, highlighting progress in its SIM0505 and LNCB74 ADC programs, including Fast Track designation for SIM0505 in platinum-resistant ovarian cancer and plans to present Phase 1 data at ASCO 2026.
Tickers: $NXTC